Ocrelizumab, Primary Progressive Multiple Sclerosis (872)


exp date isn't null, but text field is


Use the button below to access this resource item.

Access this resource


All Primary Care
Acute / All Inpatient

Last reviewed: 18 March 2020

Next review: 31 July 2023

Author(s): Lesley Murray, Pushkar Shah

Author Email(s): [email protected], [email protected]

Approved By: Medicines Utilsation Subcommittee of ADTC

Document Id: 872